Companies
- Companies
- Company details
Gemin X Biotechnologies
· Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis.The company in detail
Summary
Gemin X Biotechnologies was established in late 1998, in Montréal, Québec as a spin-out of McGill University. The company completed a second round funding in May 2001. Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. The company's mission is to develop integrated capabilities in target discovery and validation, high-throughput screening, medicinal chemistry and preclinical development form the core of the company's discovery engine.
R&D
To view this information, you must subscribe to Pharmalicensing Intelligence.
Partnerships
To view this information, you must subscribe to Pharmalicensing Intelligence.
Senior management
To view this information, you must subscribe to Pharmalicensing Intelligence.
Board of directors
To view this information, you must subscribe to Pharmalicensing Intelligence.
Related Reports
Market Research Reports provided by reports.innovaro.com
Apr 2011 - 4 pages - $500
Nov 2010 - 43 pages - $500
Jul 2010 - 58 pages - $750
Nov 2010 - 40 pages - $500
Nov 2010 - 91 pages - $600
May 2011 - 35 pages - $500
May 2011 - 15 pages - $250
Dec 2010 - 27 pages - $500
Dec 2010 - 37 pages - $500
Oct 2010 - 28 pages - $1,000
Contact details
To view this information, you must subscribe to Pharmalicensing Intelligence.
Head office
Gemin X Biotechnologies
3576 Avenue du Parc
Suite 4310
Montreal
Quebec
H2X 2H7
Quebec (Canada)
3576 Avenue du Parc
Suite 4310
Montreal
Quebec
H2X 2H7
Quebec (Canada)
Full offices list 
Related companies
Related categories
- Industry sector
- Biotechnology / Human therapeutics
- Drug discovery
- Pharmaceutical / Prescription
- Therapeutic target
- Oncology
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us